What Valthos does
Valthos builds frontier AI systems designed to identify emerging biological threats and help design medical countermeasures in real time, aiming to shrink the response time between detecting a new pathogen and developing a treatment from months to hours. The company was founded by former Palantir life-sciences lead Kathleen McMahon and former Oxford computational neuroscience researcher Tess van Stekelenburg, with a founding team drawn from Anduril, Palantir, DeepMind, OpenAI, Stanford's Arc Institute and MIT's Broad Institute. Valthos emerged from stealth in October 2025 backed by the OpenAI Startup Fund, Lux Capital and Founders Fund.
Valthos is a healthcare tool on Falcoscan. Frontier AI systems that detect biological threats and design countermeasures. Falcoscan rates Valthos with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. Valthos is founded in 2024, currently at Seed stage. Pricing: Paid.